Review Article| Volume 20, ISSUE 1, P26-39, January 1998

The role of clobetasol propionate emollient 0.05% in the treatment of patients with dry, scaly, corticosteroid-responsive dermatoses

  • Marsha L. Gordon
    Address correspondence to: Marsha L. Gordon, MD, Department of Dermatology, Mount Sinai Medical Center, One Gustave L. Levy Place, New York, NY 10029-6574.
    Mount Sinai Medical Center, New York, New York U.S.A.
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.


      The use of topical corticosteroids has significantly enhanced the treatment of patients with dermatoses such as psoriasis and eczema. In particular, group I high-potency corticosteroids such as clobetasol propionate have proved safe and effective for limited-course treatment of inflammatory and pruritic manifestations of moderate-to-severe corticosteroid-responsive dermatoses. At the same time, much effort has gone into devising more effective strategies for addressing the dry skin conditions associated with various dermatologic disorders. An emollient added to a steroid, although not itself an active ingredient, can help restore the normal moisturizing process of the skin; this may be particularly important in soothing the discomfort of the dry skin conditions often encountered in moderate-to-severe dermatoses. In addition, the degree of epidermal hydration can affect the penetration of steroids into the skin. Therefore, successful outcomes in the treatment of patients with corticosteroid-responsive dermatoses may involve more than use of an effective topical steroid. This article examines a currently available cream formulation of 0.05% clobetasol propionate containing moisturizers—emollients, dimethicone, and a humectant—that may contribute to improved moisture content in treated skin. A review of recent studies shows that clobetasol propionate emollient cream is well tolerated and effective in courses of up to 4 weeks for the treatment of patients with psoriasis or atopic dermatitis


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ramsey DL
        • Benimoff A
        The ability of primary care physicians to recognize the common dermatoses.
        Arch Dermatol. 1981; 117: 620-622
      1. Physician Drug and Diagnosis Audit. Scott Levin, January—December 1995. Data on file. Glaxo Wellcome; Research Triangle Park, NC.

        • Larsen FS
        • Diepgen T
        • Svensson Å
        The occurrence of atopic dermatitis in North Europe: An international questionnaire study.
        J Am Acad Dermatol. 1996; 34: 760-764
        • Ginsburg IH
        Coping with psoriasis: A guide for counseling patients.
        Cutis. 1996; 57: 323-325
        • Sulzberger MD
        • Witten VH
        The effect of topically applied compound I in selected dermatoses.
        J Invest Dermatol. 1952; 19: 101-102
        • Stoughton RB
        • Cornell RC
        Review of super-potent topical corticosteroids.
        Semin Dermatol. 1987; 6: 72-76
        • Stoughton RB
        • Cornell RC
        in: Fitzpatrick TB Eisen AZ Wolff K Dermatology in General Medicine. McGraw-Hill, New York1993: 2846-2850
        • Fusaro RM
        • Kingsley DN
        Topical glucocorticoids: How they are used and misused.
        Postgrad Med. 1986; 79: 283-291
        • Parish LC
        • Witkowski JA
        • Muir JG
        Topical corticosteroids.
        Int J Dermatol. 1985; 24: 435-436
        • Pakes GE
        • Kamm AR
        Topical clobetasol propionate.
        in: Maibach HI Surber C Topical Corticosteroids. Karger, Basel, Switzerland1992: 370-387
        • Jacobson C
        • Cornell RC
        • Savin RC
        A comparison of clobetasol propionate 0.05 percent ointment and an optimized betamethasone dipropionate 0.05 percent ointment in the treatment of psoriasis.
        Cutis. 1986; 37: 213-220
        • Ellis CN
        • Van Scott EJ
        Clobetasol propionate cream versus halcinonide cream in psoriasis.
        Int J Dermatol. 1986; 25: 332-333
        • Olsen EA
        • Cram DL
        • Ellis CN
        • et al.
        A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate-to-severe scalp psoriasis.
        J Am Acad Dermatol. 1991; 24: 443-447
        • Björnberg A
        • Hellgren L
        Treatment of psoriasis with clobetasol propionate: A double-blind comparison with betamethasone valerate.
        Curr Med Res Opin. 1975; 3: 36-38
        • Jegasothy B
        • Jacobson C
        • Levine N
        • et al.
        Clobetasol propionate versus fluocinonide cream in psoriasis and eczema.
        Int J Dermatol. 1985; 24: 461-465
      2. Maloney JM, Morman MR, Stewart DM, et al. Clinical efficacy and safety of an emollient cream formulation of clobetasol propionate in the treatment of moderate to severe atopic dermatitis In press.

        • Olsen EA
        • Cornell RC
        Topical clobetasol-17-propionate: Review of its clinical efficacy and safety.
        J Am Acad Dermatol. 1986; 15: 246-255
      3. Data on file. Glaxo Dermatology; Research Triangle Park, NC; 1997.

        • Elson ML
        • Terezakis NK
        The use of skin-care products and cosmeceuticals in the practice of dermatology.
        Cosmetic Dermatol. 1994; 7: 29-32
        • Jackson EM
        Moisturizers of today.
        J Toxicol Cutaneous Ocul Toxicol. 1992; 11: 173-184
        • Jorizzo JL
        • Magee K
        • Stewart DM
        • et al.
        Clobetasol propionate emollient 0.05 percent: Hypothalamic-pituitary-adrenal-axis safety and four-week clinical efficacy results in plaque-type psoriasis.
        Cutis. 1997; 60: 55-60
        • Werner YLVA
        The water content of the stratum corneum in patients with atopic dermatitis.
        Acta Derm-Venereol (Stockh). 1986; 66: 281-284
        • Nicol NH
        Current considerations and management of atopic dermatitis.
        Dermatol Nurs. 1990; 2: 129-137
        • Jackson EM
        The science of cosmetics.
        Am J Contact Dermatitis. 1996; 7: 247-250
        • Drake LA
        • Ceilley RE
        • Cornelison RL
        • et al.
        Guidelines of care for atopic dermatitis.
        J Am Acad Dermatol. 1992; 36: 485-488
        • Watsky KL
        • Freije L
        • Leneveu M-C
        • et al.
        Water-in-oil emollients as steroid-sparing adjunctive therapy in the treatment of psoriasis.
        Cutis. 1992; 50: 383-386
        • Jackson EM
        Latest information on how moisturizers work.
        Cosmetic Dermatol. 1992; 5: 35-37
      4. Lowe NJ 2nd ed. Practical Psoriasis Therapy. Mosby-Year Book, Philadelphia1993: 54-57
        • Harvey SC
        Topical drugs.
        in: Gennaro AR 18th ed. Remington's Pharmaceutical Sciences. Mack Publishing, Easton, Pa1990: 758
        • Arndt KA
        3rd ed. Manual of Dermatologic Therapeutics. Little, Brown, Boston1984: 300-301
        • Piacquadio DJ
        Topical corticosteroids in clinical practice: Focus on fluticasone propionate.
        Cutis. 1996; 57: 4-9
        • Johnson A
        Non-steroid skin cream in traumatic dermatoses: A clinical open evaluation.
        Med J Aust. 1976; 1: 111-113
        • Comaish JS
        • Greener JS
        The inhibiting effect of soft paraffin on the Köbner response in psoriasis.
        Br J Dermatol. 1976; 94: 195-200
        • Harding SM
        • Sohail S
        • Busse MJ
        Percutaneous absorption of clobetasol propionate from novel ointment and cream formulations.
        Clin Exp Dermatol. 1985; 10: 13-21